We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

7 hedge funds and large institutions have $2.13M invested in Loncar China BioPharma ETF in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

17% more funds holding

Funds holding: 6 → 7 (+1)

13% more capital invested

Capital invested by funds: $1.9M → $2.13M (+$240K)

1.02% more ownership

Funds ownership: 16.24% → 17.26% (+1%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$325K
2
FEM
Fulcrum Equity Management
Texas
+$15.9K
3
WEC
Winslow Evans & Crocker
Massachusetts
+$14.4K
4
Osaic Holdings
Osaic Holdings
Arizona
+$1.07K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$223K
2
UBS Group
UBS Group
Switzerland
-$15.1K

CHNA Hedge Fund Activity: Q4 2020 in Review

7 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q4 2020, worth a combined $2.13M — up 13% from $1.9M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CHNA positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $325K. The largest seller was Jane Street, cutting an estimated $223K.

  • 7 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q4 2020, up from 6 in Q3 2020.
  • Funds reported $2.13M of Loncar China BioPharma ETF stock for Q4 2020, up 13% quarter-over-quarter.
  • 2 funds opened new Loncar China BioPharma ETF positions in Q4 2020 and 1 closed out, a net change of +1 holder.
  • The largest Loncar China BioPharma ETF buyer in Q4 2020 was Citadel Advisors, an estimated $325K added.
  • The largest Loncar China BioPharma ETF seller in Q4 2020 was Jane Street, an estimated $223K sold.

Based on aggregated 13F filings for Q4 2020.